Bone matters: Defining the burden of skeletal disease in telomere biology disorders
Abstract
Abstract Introduction: Telomere biology disorders (TBDs) are caused by germline pathogenic or likely pathogenic variants in telomere maintenance genes and result in multisystem manifestations, including impaired bone health. Patients with TBDs experience reduced bone mineral density (BMD), avascular necrosis, and increased rates of fragility fractures. However, the underlying mechanisms of these bone complications remain poorly understood, and no TBD-specific treatments for bone health currently exist. Our objective was to characterize the clinical features, management, and outcomes of TBD-related bone health issues, including fractures and reduced BMD. Methods: We conducted a retrospective, multicenter, international cohort study using data from 232 patients with TBDs enrolled across 12 centers participating in the Clinical Care Consortium of Telomere-Associated Ailments. Medical records were reviewed for fracture history and BMD assessments by dual-energy X-ray absorptiometry (DXA). The primary endpoint was fracture incidence; secondary endpoints included BMD assessment and fracture management. Data were stratified by pediatric (≤18 years) and adult (>18 years) age groups. Analyses were based on data availability; specific denominators are provided where applicable. Result: Data were available for 53 (23%) pediatric and 179 (77%) adult patients. TERT mutations were the most frequently identified variants in both groups (28% pediatric, 23% adult). Fractures occurred in 25% (13/53) of pediatric patients and 35% (62/178) of adults. In contrast, fractures are estimated to occur in 10-15% of the general pediatric population. The median age at first fracture was 8.2 years (range 2.5–17) in children and 29.2 years (range 18.3–66.9) in adults. Among those with fracture data (n=20 pediatric, n=22 adult), fragility fractures were more common in adults (57%) versus predominantly traumatic fractures in children (61%). Multiple fractures occurred in 65% of affected pediatric patients and 45% of affected adults. Fracture management also differed: non-surgical treatments were used in 60% of pediatric fractures (n=12/20) versus 36% (n=8/22) of adult fractures; surgical interventions were more common in adults (36%). The inheritance pattern (autosomal dominant versus recessive or X-linked) was not associated with fracture risk but the subset of patients with CTC1 mutations were associated with increased fracture risk (n=5 of 124 patients with fracture history, 4% vs n=2 of 247 patients with no fracture history, 0.8%; p=0.04). We also assessed whether vascular manifestations were associated with fracture risk comparing patients with and without fractures. Pulmonary arteriovenous malformations (AVMs) were significantly more common in patients with fractures (17%, 7/42) versus those without (5.4%, 6/112; p=0.04). No significant differences were found in rates of retinal vasculopathy or hemorrhage (13% vs 7.2%, p=0.23) or gastrointestinal bleeding (22% vs 16%, p=0.35). DXA data were available for 171 patients (22 pediatric, 149 adult). The median age at first DXA was 11.4 years (range 4–17.7) for children and 58.2 years (range 20.8–79.4) for adults. Among pediatric patients, the median lumbar spine Z-score was –1.2 (IQR –3.0 to –0.2, n=18), with 39% (7/18) showing a Z-score < –2. Among adults, the median femoral neck T-score was –1.1 (IQR –1.7 to –0.5, n=118), with 21% (29/138) demonstrating T-scores < –2, indicating low BMD. Conclusions: Fractures and reduced BMD are common in both pediatric and adult patients with TBDs, with a substantial burden of early-onset and recurrent fractures. Our findings underscore the importance of early bone health screening and surveillance in TBDs and suggest a possible link between vascular abnormalities and skeletal fragility in this population that requires further study.
Article Details
Authors (29)
Jane Koo
1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States
Lindsey N. Hornung
3Cincinnati Children's Hospital Medical Center, Division of Biostatistics and Epidemiology, Cincinnati, United States
Jonathan Howell
1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States
Ethan Lawhorn
1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States
Dawn Comstock
4Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Boston, United States
Christopher Reilly
6Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States
Alejandro Ferrer
4Mayo Clinic, Rochester, United States
Abhishek Mangaonkar
1Mayo Clinic, Rochester, United States
Bianca Barredo
9University of Wisconsin Carbone Cancer Center, Madison, United States
Jane Churpek
2University of Wisconsin-Madison, Madison, United States
Fabian Beier
5Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Germany
Linda Frazier
10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States
Pamela Vincent
10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States
Paul Szabolcs
10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States
Jessica Uhrich
13St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States
Marcin Wlodarski
2St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States
Nicholas Gloude
14Rady Children's Hospital San Diego, Division of Pediatric Hematology/Oncology, San Diego, United States
Helena Yu
Divya Koura
6University of California San Diego Moores Cancer Center, San Diego, CA
Tanim Jain
13Moores Cancer Center, San Diego, United States
Orna Steinberg-Shemer
16Tel Aviv University, Gray Faculty of Medical and Health Sciences, Tel Aviv, Israel
Christen Ebens
1University of Minnesota, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Minneapolis, United States
Paul Wratkowski
19University of Minnesota, Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, Minneapolis, United States
Soundarya Avantsa
20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States
Emma Groarke
1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States
Bhavisha Patel
1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States
Sharon Savage
20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States
Neelam Giri
3National Institutes of Health, Clinical Genetics Branch, National Cancer Institute, Bethesda, United States
Kasiani Myers
1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States